Role of parathyroidectomy on anemia control and erythropoiesis-stimulating agent need in secondary hyperparathyroidism of chronic kidney disease. A retrospective study in 30 hemodialysis patients

Annali Italiani di Chirurgia

Volumn 84, Issue 1, 2013, Pages 25-31

  Conzo, Giovanni ^a   Perna, Alessandra ^a   Pietra, Cristina Della ^a   Esposito, Daniela ^a   Nunziata, Anna ^a   Palazzo, Antonietta ^a   Pizza, Alessandra ^a   Satta, Ersilia ^a   Sciascia, Valerio ^a   Santini, Luigi ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Anemia; Chronic kidney disease; Erythropoietin; Parathyroidectomy; Secondary hyperparathyroidism

Indexed keywords

ANTIANEMIC AGENT;

ANEMIA; DRUG UTILIZATION; FEMALE; HUMAN; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PARATHYROIDECTOMY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TIME;

ANEMIA; DRUG UTILIZATION; FEMALE; HEMATINICS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PARATHYROIDECTOMY; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84884231745     PISSN: 2239253X     EISSN: 2239253X     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Vos FE, Schollum JB, Coulter CV, Doyle TCA, Dufful SB, Walker RJ Red blood cell survival in long-term dialysis patients. Am J Kidney Dis, 2011; 58(4):591-98.
2. Bogin E, Massry SG, Levi J, Djaldeti M, Bristol G, Smith Effect of parathyroid hormone on osmotic fragility of human erythrocytes. J Clin Invest, 1982; 9:1017-25.
3. Zingraff J, Drueke T, Marie P, Man NK, Jungers P, Bordier P Anemia and secondary hyperparathyroidism. Arch Intern Med, 1979; 139:889-91.
4. Meytes D, Bogin E, Ma A, Dukes PP, Massry S Effect of parathyroid hormone on erythropoiesis. J Clin Invest 1981; 67: 1263-269.
5. Foley RN Treatment of anemia in chronic kidney disease: known, unknown, and both. J Blood Med, 2011; 2:103-12.
6. Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease: drug safety communication - modified dosing recommendations (epoetin alfa (marketed as epogen and procrit) and darbepoetin alfa (marketed as aranesp) [06/24/2011. Drug SafetyCommunication-FDA].
7. Trunzo JA, MCHenry CR, Schulak JA, Wilhelm SM Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism. Surgery, 2008; 144(6):915-18.
8. Chow TL, Chan TT, Ho YW, Lam SH Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Arch Surg, 2007; 142:644-48.
9. Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol 2004; 15 Suppl 1:S21-4.
10. Jemcov TK, Petakov M, Bogdanovic A, Djukanovic L, Lezaic VD Parathyroidectomy and improving anemia. Arch Surg, 2008; 143(1):97-8.
11. National Clinical Guideline Centre (UK): Anaemia management in chronic kidney disease: Rapid update 2011. London: Royal College of Physicians (UK); 2011. National Institute for Health and Clinical Excellence: Guidance.
12. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis, 2003; 42:S1-202.
13. Tominaga Y, Matsouka S, Sato T. Surgical indications and procedures of parathyroidectomy in patients with chronic kidney disease. Therapeutic Aphresis and Dialysis 2005; 9(1): 44-47.
14. Dawson-Saunders B, Trapp RG (1990) Basic and clinical biostatistics. East Norwalk, Connecticut: Appleton & Lange, CT, U.S.A. 329 pp.
15. De Santo RM, Esposito MG, Cesare CM, et al. Parathyroidectomy improves the quality of sleep in maintenance hemodialysis patients with severe hyperparathyroidism. J Nephrol 2008; 21 Suppl 13:S92-6.
16. Conzo G, Perna AF, Sinisi AA et al. Total parathyroidectomy without autotransplantation in the surgical treatment of secondary hyperparathyroidism of chronic kidney disease. J Endocrinol Invest 2012; 35: 8-13.
17. De Santo RM, Livrea A, De Santo NG et al. The high prevalence of alexithymia in hemodialyzed patients with secondary hyperparathyroidism unsuppressed by medical therapy is cured by parathyroidectomy. J Ren Nutr 2010; 20(5 Suppl):S64-70.
18. Conzo G, Palazzo A, Della Pietra C, Stanzione F, Candilio G, Docimo G, Livrea A Trattamento chirurgico dell'iperparatiroidismo secondario.Studio clinico in 70 pazienti. Ann Ita Chir, 2010; 81:413-19
19. Conzo G, Perna A, Avenia N, de Santo RM, Della Pietra, Palazzo, Sinisi A, Stanzione A, Santini L Evaluation of "putative" role of intraoperative intact parathyroid hormone assay during parathyroidectomy for secondary hyperparathyroidism. A retrospective study on 35 consecutive patients. Endocrine DOI 10.1007/s 12020 - 012-9648-5 Publishe on line. 16 march 2012-03-25
20. Yasunaga C, Matsuo K, Yanagida T, Matsuo S, Nakamoto M, Goya T Early effects of parathyroidectomy on erythropoietin production in secondary hyperparathyroidism. Am J Surg, 2002; 183(2):199-204.
21. Lee CT, Chou FF, Chang HW, et al. Effects of parathyroidectomy on iron homeostasis and erythropoiesis in hemodialysis patients with severe hyperparathyroidism. Blood Purif, 2003; 21(6):369-75.
22. Lin CL, Hung CC, Yang CT, Huang CC Improved anemia and reduced erythropoietin need by medical or surgical intervention of secondary hyperparathyroidism in hemodialysis patients. Ren Fail, 2004; 26(3):289-95.
23. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Grou:. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl, 2009; 113:S1-130.
24. Triponez F, Clark OH, Vanrenthergem Y, et al.: Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann Surg, 2008; 248(1):18-30.
25. Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic: Erytropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif, 2010; 29:1-12.
26. Eschbach J, Adamson J Recombinant human erythropoietin: Implication for nephrology. Am J Kidney Dis, 1988; 11:203-209.
27. NFK-DOQI: Clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis, 1997[Suppl 3]:S192-S240.
28. Regidor DL, Kopple JD, Kovesdy CP, et al.: Associations between changes in hemoglobin and administered erytropoiesis-stimulating agents and survival in hemodialysis patients. J Am Soc Nephrol, 2006; 17 (4); 1181-191.
29. Rao DS, Shis MS, Mohini R Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med, 1993; 328:171-75.
30. Johnson DW, Pollock CA, Macdougall IC Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton,) 2007; 12(4):321-30.
31. Goicoechea M, Vazquez MI, Ruiz MA, Gomez-Campdera F, Perez-Garcìa R, Valderràbano F Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. Nephron, 1998; 78(1):23-7.
32. McGonigle RJS, Wailin JD, Husserl F, et al. Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure. J Lab Clin Med, 1984; 104(6): 1815-817.
33. Urena P, Eckardt KU, Sarfati E, et al. Serum erytropoietin and erytropoiesis in primary and secondary hyperparathyroidism: effect of parathyroidectomy. Nephron, 1991; 59(3): 384-393.
34. Washio M, Iseki K, Onoyama K, et al. Elevation of serum erytropoietin after subtotal parathyroidectomy in chronic haemodialysis patients. Nephrol Dial Transplant, 1992; 7(2):121-24.
35. Goicoechea M, Gomez-Campdera F, Polo JR, et al.:Secondary hyperparathyroidism as cause of resistance to treatment with erytropoietin: Effect of parathyroidectomy. Clin Nephrol, 1996; 45:420-21.
36. Coen G, Calabria S, Bellinghieri G, et al.: Parathyroidectomy in chronic renal failure: short- and long-term results on parathyroid function, blood pressure and anemia. Nephron, 2001; 88(2):149-55.
37. Oshiro Y, Tanaka H, Okimoto N A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet. Clin Exp Nephrol, 2011; 15(4):607-10.
38. Mpio I, Boumendjel N, Karaaslan H, et al. Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study. Nephrol Ther, 2011; 7(4):229-36.
39. Garcia-Canton C, Palomar R, Moreno A, et al. Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism. Nephron, 1996; 74:444.